Sector News

Novartis to close Puerto Rico plant by 2019, move some operations to Lincoln plant

January 19, 2015
Life sciences
(AP) — Novartis AG is closing its manufacturing plant in Puerto Rico as part of a major overhaul of its business, the company said in a statement Friday.
 
The Switzerland-based company said the shutdown of its Humacao plant will conclude in early 2019. Some 270 employees will be laid off.
 
Novartis said it will transfer some manufacturing and packaging operations to companies including Eli Lilly & Co. Some operations also will be transferred to Novartis’ manufacturing plant in Lincoln, Nebraska.
 
Puerto Rico’s Industrial Development Company said it would seek to sell the plant to a local company or to one taking over some of Novartis’ operations.
 
The U.S. territory is still considered one of the world’s leading centers for pharmaceutical manufacturing, but the sector has been shrinking. The government has been offering incentives for manufacturing plants to expand and is pushing to diversify its manufacturing base by seeking aerospace and information technology companies.
 
Novartis’ Humacao plant opened in 1975.

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”